PMS2 expression loss was reported in a variety of human. However, its importance has not been fully understood in cervical carcinoma. The aim of this study was to determine the expression of PMS2 in cervical carcinoma and evaluate the significance of mismatch repair gene PMS2 regulated by glycogen synthase kinase 3beta (GSK−3beta) in chemosensitivity.

We examined PMS2 and phosphorylated GSK−3beta(s9) expression in cervical carcinoma tissues using immunohistochemical staining. Furthermore, we detected PMS2 expression in HeLa cells and evaluate the interaction with GSK−3beta after transfection with GSK−3beta by small interference RNA (siRNA), co−immunoprecipitation and immunoblotting. We also evaluated the effect of PMS2 transfection on HeLa cells' chemosensitivity to cisplatin treatment.

We found significant downregulation of PMS2 in cervical carcinoma, which was negatively associated with phosphorylated GSK−3beta (s9). Furthermore, we demonstrated GSK−3beta transfection was able to interact with PMS2 and enhance PMS2 production in HeLa cells, and increased PMS2 production was responsible for enhanced chemosensitivity.

Our results provide the evidence that stabilization of PMS2 production by GSK−3beta was important to improve chemosensitization, indicating the significance of GSK−3beta −related PMS2 downregulation in the development of cervical carcinoma and in developing a potential strategy for chemotherapy.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.